Axsome Therapeutics, Inc.

AXSM Healthcare Biotechnology

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024. In the quarter to June 2026, revenue grew 45.5%, EPS fell 2.06%, free cash flow fell 2.98% and total debt rose 4.66%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

157.14 4.65 −2.87%
Market cap
$8.5B
P/E
0.0×
Fwd P/E
−121×
Dividend yield
—
F-score
5/9
Altman Z
6.91
Beneish M
−2.53
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 5 5 5

+8 more TTM periods

ROE
(245.10%) (349.38%) (252.11%) (275.50%)
ROA
(27.35%) (28.74%) (29.11%) (37.30%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(97.28%) (109.12%) (86.93%) (111.61%)
Average Days of Receivables
130.41 129.39 128.32 127.79
Free Cash Flow per Share
(1.39) (1.39) (1.89) (2.03)
Free Cash Flow
(71.96) (70.99) (93.88) (101.39)
Other line items

Show all line items

Columns are period end dates